News|Videos|March 31, 2026

Could Pluvicto Be a First-Line Systemic Treatment for Patients with Oligometastatic Hormone-Sensitive PCa?

Name: Could Pluvicto Be a First-Line Systemic Treatment for Patients with Oligometastatic Hormone-Sensitive PCa?
Uploaded: 2026-03-31T10:05:00Z
Duration: 10 min 35 s
Description: In a recent interview, James Nagarajah, M.D., discussed new phase 2 research demonstrating significantly delayed disease progression in a cohort of patients with oligometastatic hormone-sensitive prostate cancer treated with 177-Lu-PSMA-617 and complete remission in nearly a quarter of these patients.

Author(s)Jeff Hall

In a recent interview, James Nagarajah, M.D., discussed new phase 2 research demonstrating significantly delayed disease progression in a cohort of patients with oligometastatic hormone-sensitive prostate cancer treated with 177-Lu-PSMA-617 and complete remission in nearly a quarter of these patients.

New research suggests that the theranostic agent ¹⁷⁷Lu-PSMA-617 may provide a significant impact in treating oligometastatic hormone-sensitive prostate cancer (HSPC) and potentially deferring the use of androgen deprivation therapy (ADT).